Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will attend the UBS China A-Share Conference 2026 in Shenzhen on September 1 (IMAGE)

InSilico Medicine

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will attend the UBS China A-Share Conference 2026 in Shenzhen on September 1

Caption

participating in a panel discussion and delivering a speech. As a leader in AI drug discovery and frontier technology, Dr. Ren will detail how Insilico Medicine uses AI to reshape R&D paradigms, enhancing efficiency and innovation value.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.